ETS-related gene ERG expression in AML patients is significantly associated with NPM1 mutation status.
Hämäläinen
Mauri
M
Juvonen
Vesa
V
Häikiö
Satu
S
Lakkala
Taina
T
Johansson
Janita
J
Pelliniemi
Tarja-Terttu
TT
Salmi
Toivo T
TT
Remes
Kari
K
Kairisto
Veli
V
D000293:Adolescent; D000328:Adult; D000368:Aged; D002648:Child; D002675:Child, Preschool; D005260:Female; D015973:Gene Expression Regulation, Leukemic; D006801:Humans; D007223:Infant; D015470:Leukemia, Myeloid, Acute / Q000235:genetics* / Q000401:mortality / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009154:Mutation; D009687:Nuclear Proteins / Q000235:genetics* / Q000378:metabolism; D000090243:Nucleophosmin; D011379:Prognosis; D050783:Proto-Oncogene Proteins c-ets / Q000235:genetics; D016019:Survival Analysis; D015534:Trans-Activators / Q000096:biosynthesis* / Q000235:genetics; D000071230:Transcriptional Regulator ERG; D055815:Young Adult; D051941:fms-Like Tyrosine Kinase 3 / Q000235:genetics / Q000378:metabolism
C072312:ERG protein, human; C000716967:NPM1 protein, human; D009687:Nuclear Proteins; D050783:Proto-Oncogene Proteins c-ets; D015534:Trans-Activators; D000071230:Transcriptional Regulator ERG; D000090243:Nucleophosmin; C497970:FLT3 protein, human; D051941:fms-Like Tyrosine Kinase 3